Read-only review
View briefClient-facingResearch-use onlyLung adenocarcinoma
Client review for Lung adenocarcinoma demo cohort.
Review the research-use deliverables: mutation relevance signals, candidate drug-repurposing hypotheses, report status, and validation next steps.
Cohort
Lung adenocarcinoma demo cohort
De-identified demo dataset
Latest run
15
Mutation signals scored
Report
ready
Evidence brief status
Boundary
R&D
Expert review required
Review path
1Cohort receivedDe-identified mutation file checked against the demo schema.Complete
2Signals rankedMutation relevance signals prepared for research review.Complete
3Hypotheses draftedCandidate drug-repurposing hypotheses include limitations and evidence tags.In review
4Report exportEvidence brief is available for client-side review comments.Ready
Mutation signals
Top items for review
1. EGFR L858REGFR/ERBB signalling94
2. TP53 R175Hp53 tumour suppressor pathway88
3. KRAS G12CRAS/MAPK signalling82
Hypotheses
Candidate classes
1. EGFR inhibitor classLinked to EGFR L858R
2. MEK pathway inhibitor classLinked to KRAS G12D
3. MEK pathway inhibitor classLinked to KRAS G12C
Research-use boundary
Research-use only. ONCOQ.TECH produces evidence-ranked mutation signals and drug-repurposing hypotheses for investigation. Outputs are not clinical recommendations and must be reviewed by qualified experts before any validation or downstream use.
Evidence brief is ready for read-only review.